Cargando…

Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome

Acute lung injury and acute respiratory distress syndrome (ARDS) represent a heterogenous group of lung disease in critically ill patients that continues to have high mortality. Despite the increased understanding of the molecular pathogenesis of ARDS, specific targeted treatments for ARDS have yet...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadikot, Ruxana T., Kolanjiyil, Arun V., Kleinstreuer, Clement, Rubinstein, Israel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945951/
https://www.ncbi.nlm.nih.gov/pubmed/31988911
http://dx.doi.org/10.1159/000477086
_version_ 1783485267696418816
author Sadikot, Ruxana T.
Kolanjiyil, Arun V.
Kleinstreuer, Clement
Rubinstein, Israel
author_facet Sadikot, Ruxana T.
Kolanjiyil, Arun V.
Kleinstreuer, Clement
Rubinstein, Israel
author_sort Sadikot, Ruxana T.
collection PubMed
description Acute lung injury and acute respiratory distress syndrome (ARDS) represent a heterogenous group of lung disease in critically ill patients that continues to have high mortality. Despite the increased understanding of the molecular pathogenesis of ARDS, specific targeted treatments for ARDS have yet to be developed. ARDS represents an unmet medical need with an urgency to develop effective pharmacotherapies. Multiple promising targets have been identified that could lead to the development of potential therapies for ARDS; however, they have been limited because of difficulty with the mode of delivery, especially in critically ill patients. Nanobiotechnology is the basis of innovative techniques to deliver drugs targeted to the site of inflamed organs, such as the lungs. Nanoscale drug delivery systems have the ability to improve the pharmacokinetics and pharmacodynamics of agents, allowing an increase in the biodistribution of therapeutic agents to target organs and resulting in improved efficacy with reduction in drug toxicity. Although attractive, delivering nanomedicine to lungs can be challenging as it requires sophisticated systems. Here we review the potential of novel nanomedicine approaches that may prove to be therapeutically beneficial for the treatment of this devastating condition.
format Online
Article
Text
id pubmed-6945951
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-69459512020-01-27 Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome Sadikot, Ruxana T. Kolanjiyil, Arun V. Kleinstreuer, Clement Rubinstein, Israel Biomed Hub Review Acute lung injury and acute respiratory distress syndrome (ARDS) represent a heterogenous group of lung disease in critically ill patients that continues to have high mortality. Despite the increased understanding of the molecular pathogenesis of ARDS, specific targeted treatments for ARDS have yet to be developed. ARDS represents an unmet medical need with an urgency to develop effective pharmacotherapies. Multiple promising targets have been identified that could lead to the development of potential therapies for ARDS; however, they have been limited because of difficulty with the mode of delivery, especially in critically ill patients. Nanobiotechnology is the basis of innovative techniques to deliver drugs targeted to the site of inflamed organs, such as the lungs. Nanoscale drug delivery systems have the ability to improve the pharmacokinetics and pharmacodynamics of agents, allowing an increase in the biodistribution of therapeutic agents to target organs and resulting in improved efficacy with reduction in drug toxicity. Although attractive, delivering nanomedicine to lungs can be challenging as it requires sophisticated systems. Here we review the potential of novel nanomedicine approaches that may prove to be therapeutically beneficial for the treatment of this devastating condition. S. Karger AG 2017-06-27 /pmc/articles/PMC6945951/ /pubmed/31988911 http://dx.doi.org/10.1159/000477086 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Review
Sadikot, Ruxana T.
Kolanjiyil, Arun V.
Kleinstreuer, Clement
Rubinstein, Israel
Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
title Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
title_full Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
title_fullStr Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
title_full_unstemmed Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
title_short Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
title_sort nanomedicine for treatment of acute lung injury and acute respiratory distress syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945951/
https://www.ncbi.nlm.nih.gov/pubmed/31988911
http://dx.doi.org/10.1159/000477086
work_keys_str_mv AT sadikotruxanat nanomedicinefortreatmentofacutelunginjuryandacuterespiratorydistresssyndrome
AT kolanjiyilarunv nanomedicinefortreatmentofacutelunginjuryandacuterespiratorydistresssyndrome
AT kleinstreuerclement nanomedicinefortreatmentofacutelunginjuryandacuterespiratorydistresssyndrome
AT rubinsteinisrael nanomedicinefortreatmentofacutelunginjuryandacuterespiratorydistresssyndrome